A股異動 | 方盛製藥午後一度觸及漲停 小兒荊杏止咳顆粒註冊申請已審批完畢
格隆匯12月19日丨方盛製藥(603998.SH)午後直線拉昇,盤中一度觸及漲停,現報8.49元,漲9.13%,暫成交1.6億元,最新總市值36.9億元。方盛製藥昨日盤後發公告稱,公司查詢國家藥監局網站獲悉,公司提交的“小兒荊杏止咳顆粒”國產藥品註冊申請處於“審批完畢-待制證”狀態。由於國家藥監局官網無法查詢到上述藥品的批准文號與具體通知內容,因此,公司尚不知曉最終審批結果是否通過。公司將待取得國家藥監局簽發的正式文件後,按照有關規定及時披露所涉及的藥品信息、研發投入、市場狀況等有關情況。此外據悉,受益於工業大麻概念等,方盛製藥今年以來股價已累漲逾80%。今年前三季度公司實現營收8.198億元,同比增長2.77%;歸屬於上市公司股東的淨利潤7045.84萬元,同比增長15.64%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.